Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Eye disease biotech launches with $100M, Roche rival in clinic
Ollin Biosciences has already enrolled 150 patients in a phase 1b trial pitting its bispecific antibody against Roche's blockbuster eye med Vabysmo.
Darren Incorvaia
Sep 17, 2025 6:30am
Opthea ramps up cuts to 85% of staff, including CEO
Aug 19, 2025 7:35am
Boehringer inks another eye disease deal, this time with Palatin
Aug 18, 2025 10:30am
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Jul 24, 2025 5:00am
Cloudbreak plots phase 3 after eye drop passes midstage test
Jul 21, 2025 4:35am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
